U
NYMX

UBS’s Nymox Pharmaceutical Corp NYMX Stock Holding History

UBS’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,100
Closed -$40K – 10877
2014
Q2 		$40K Buy
+8,100
New +$41.7K ﹤0.01% 7179
2013
Q3 		– Sell
-7,500
Closed -$38K – 10795
2013
Q2 		$38K Buy
+7,500
New +$38K ﹤0.01% 7097

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS's NYMX Position: Q3 2014 in Review

UBS reduced its Nymox Pharmaceutical Corp (NYMX) stake by 33% in Q3 2014, selling an estimated $3.36K and leaving 1,382 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9328.

UBS first reported a position in NYMX in Q2 2013 and has held it in 6 quarters since. The position peaked at $28K in Q4 2013. 29 funds tracked by Wall St. Rank hold NYMX as of Q3 2014.

  • UBS held 1,382 shares of Nymox Pharmaceutical Corp worth $6K as of Q3 2014.
  • UBS sold 686 Nymox Pharmaceutical Corp shares in Q3 2014, an estimated $3.36K.
  • Nymox Pharmaceutical Corp made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9328 holding.
  • UBS first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and has held it in 6 quarters since.
  • UBS's Nymox Pharmaceutical Corp position peaked at $28K in Q4 2013.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.